Neumora Therapeutics, Inc. Common Stock (NMRA) Stock
NASDAQ · NMRA
Key stats
- Market cap
- $88.87M
- Price / Earnings ratio
- -0.4x
- EPS (TTM)
- -$1.23
- Volume
- Loading
- 52-week high
- $3.65
- 52-week low
- $0.32
Source: third-party data provider, as of November 13, 2026
Compare with NMRA
Recent news

Business Wire
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NMRAJune 18, 2026
Business Wire
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NMRA

Zacks Investment Research
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRAJune 16, 2026
Zacks Investment Research
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRA

Stocktwits
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NMRAJune 15, 2026
Stocktwits
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NMRA

Reuters
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NMRAJune 15, 2026
Reuters
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NMRA
Technical indicators
- RSI 14
- 45.04
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.03
- SMA 50
- $0.64
- Price below SMA 50
- EMA 50
- $0.68
- Price below EMA 50
- SMA 200
- $1.72
- Price below SMA 200
- EMA 200
- $1.50
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
595M393M196M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-236.9M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Business Wire
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NMRAJune 18, 2026
Business Wire
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NMRA

Zacks Investment Research
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRAJune 16, 2026
Zacks Investment Research
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRA

Stocktwits
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NMRAJune 15, 2026
Stocktwits
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials
NMRA

Reuters
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NMRAJune 15, 2026
Reuters
Neumora Therapeutics scraps depression drug after two late-stage trial failures
NMRA

Business Wire
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
NMRAMarch 19, 2026
Business Wire
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
NMRA

InvestorPlace
7 Stocks with Strong Insider Buying: December 2023
NMRADecember 17, 2023
InvestorPlace
7 Stocks with Strong Insider Buying: December 2023
NMRA

Market Watch
IPO pipeline welcomes some profitable companies, raising hopes for a rebound
NMRANovember 20, 2023
Market Watch
IPO pipeline welcomes some profitable companies, raising hopes for a rebound
NMRA

InvestorPlace
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
NMRASeptember 28, 2023
InvestorPlace
Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO)
NMRA

Proactive Investors
Neumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developer
NMRASeptember 27, 2023
Proactive Investors
Neumora Therapeutics stock surges as Amgen confirmed as major holder of the novel depression drug developer
NMRA

Market Watch
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
NMRASeptember 27, 2023
Market Watch
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
NMRA
About Neumora Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees63
CEODr. Joshua Pinto Ph.D.
IPO DateSep 15, 2023
HeadquartersWatertown, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Joshua Pinto Ph.D. | President, CEO & Director | 1985 |
| Mr. Paul L. Berns | Executive Chairman | 1967 |
| Mr. Michael Lee Milligan | CFO & Principal Accounting Officer | 1973 |
| Dr. Daljit Singh Aurora Pharm.D. | Chief Operationg & Development officer | 1968 |
| Dr. Nicholas Brandon Ph.D. | Chief Scientific Officer | 1975 |
| Mr. Pablo Gersberg | Chief Information Officer | — |
| Mr. Jason G. Duncan J.D. | Chief Legal & Administrative Officer | 1974 |
| Helen Rubinstein | Head of Investor Relations | — |
| Ms. Amy Sullivan | Chief Human Resources Officer | — |
| Mr. David Phillips M.B.A. | Senior Vice President & Head of Quality | — |
Fundamentals
Valuation
Price-to-book value1.97
Profitability
Return on Equity-242.00%
Return on Assets-131.00%
EBITDA$-205.98M
Trading
Average volume2,048,793
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 45.04
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.06
- MACD histogram
- 0.03
- SMA 50
- $0.64
- Price below SMA 50
- EMA 50
- $0.68
- Price below EMA 50
- SMA 200
- $1.72
- Price below SMA 200
- EMA 200
- $1.50
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -13.2 | -0.8 | +13.5 | +38.3 | ||||||||
| 2024 | -11.8 | +15.6 | -23.8 | -34.8 | +8.8 | +1.3 | +29.4 | -8.9 | +23.0 | -15.2 | -11.0 | +8.2 |
| 2025 | -2.0 | -16.1 | -29.1 | -14.3 | -6.5 | -2.7 | +145.0 | +10.9 | +4.6 | +69.7 | -25.6 | -26.0 |
| 2026 | +19.9 | +76.3 | -39.1 | +18.2 | -24.2 | -6.6 | -0.6 | -18.9 | -54.9 | -32.7 | -6.0 |
Compare stocks
Market cap
$88.87M
-
-
-
Price / Earnings ratio
-0.40
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
2,048,793
-
-
-
Earnings per share
$-1.23
-
-
-



